ADXS 31164

Drug Profile

ADXS 31164

Alternative Names: ADXS-cHER2; ADXS-HER2; ADXS-HER2 construct vaccine; ADXS31-164; Lovaxin B

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Pennsylvania
  • Developer Advaxis; University of Pennsylvania
  • Class Cancer vaccines
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Osteosarcoma
  • No development reported Breast cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
  • 28 Apr 2016 ADXS 31164 receives Fast Track designation for Osteosarcoma [Parenteral] in USA
  • 28 Mar 2016 Advaxis and Children's Oncology Group plan a phase II trial for Osteosarcoma (In children, In adolescents) in USA (Advaxis pipeline, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top